S&N plans to shore up its Advanced Wound Bioactives business with the acquisition of Osiris Therapeutics but the deal may be in question as Osiris shareholders challenge the price.
Smith & Nephew (S&N) announced on March 12, 2019 that it has agreed to acquire Osiris Therapeutics for $660MM with the deal expected to close Q219. However, the deal could be in question as a group of Osiris shareholders is suing to block the acquisition. The lawsuit disputes Cantor Fitzgerald’s discounted cash flow analysis, saying it does not adequately reflect Osiris’s future growth prospects, and is based on growth rates that are about half of what Osiris has experienced in recent years, resulting in a valuation that is too low. The acquisition would add the Osiris’s Grafix and Stravix product lines to S&N’s ailing Advanced Wound Bioactives portfolio. If allowed to proceed, the acquisition would solidify S&N’s leadership in wound biologics and changes the competitive landscape in the Advanced Wound Care market...
Topics: Advanced Wound Care
As reported in SmartTRAK Financial Dashboard, every manufacturer in the Hemostats and Sealants market, except Pfizer and CryoLife, experienced revenue growth in Q418. Leading the way was Baxter with +33.1% YoY growth as it made progress with its integration of the Mallinckrodt portfolio. Ethicon and Becton Dickinson (BD) both posted solid gains, with +8.7% YoY and +6.6% YoY growth, respectively...
The US SCS Market saw another banner year in FY18, growing +17.4% YoY. Market growth was driven by new product launches, expanding indications and ongoing demand for non-narcotic alternatives that address chronic intractable pain and the opioid epidemic.
Advanced, higher priced biologics push the US OrthoBio Market higherBased on Q418/FY18 SmartTRAK Financial Dashboard reporting:
- US Bone Replacement grew +2.3% YoY, with FY18 revenues up +2.7%.
- US Cartilage Replacement increased 55.7% YoY, with FY18 revenues up 34.7%.
- US Soft Tissue Augmentation grew 2.3%, with FY18 revenues growing 9.2%.
- US Tendon Allografts posted an 8.4% YoY increase, with FY18 revenues up +3.9% YoY
- US Meniscal Implant market, with robust growth, was up 15.6% YoY for Q418 with FY18 revenues increasing by 3.0%.
Among the many topics covered in the Q418/FY18 OrthoBio Market Recap are:
SmartTRAK was cited as a source in a press release from Smith & Nephew entitled "Smith & Nephew expands in high growth regenerative medicine market through acquisition of Osiris Therapeutics, Inc."
Topics: Advanced Wound Care
Among the many topics covered in the Q418/FY18 Surgical Matrices Market Recap are:
Among the many topics covered in SmartTRAK's Q418/FY18 Spine Market Recap are:
SmartTRAK Subscribers: See only news for the Markets, Modules and Segments that you care about!
Have you ever wished that you could customize your SmartTRAK Daily Updates Email so that you can see ONLY news about the SmartTRAK Markets, Modules and Segments that you care about? And save yourself time from scrolling through all the Markets, Modules and Segments that your company subscribes to?
Topics: Your SmartTRAK News